Abstract
Immunoglobulin replacement therapy is the cornerstone of management for most primary immunodeficiency disease patients. The selection of a particular product, dose, and route of administration requires an understanding of the features of therapeutic immunoglobulin as well as patient-specific risk factors in order to maximize efficacy and tolerability and minimize risk. Individualizing therapy, taking into consideration the burdens of care, is necessary in order to optimize patient outcomes.
Keywords:
Antibody deficiency; IVIG; IgG; Immunoglobulin; SCIG; fSCIG.
Copyright © 2018 Elsevier Inc. All rights reserved.
MeSH terms
-
Agammaglobulinemia / complications
-
Agammaglobulinemia / diagnosis
-
Agammaglobulinemia / etiology
-
Agammaglobulinemia / therapy*
-
Animals
-
Clinical Decision-Making
-
Cost of Illness
-
Disease Management
-
Drug Administration Routes
-
Health Services Accessibility
-
Humans
-
Immunization, Passive / adverse effects
-
Immunization, Passive / methods
-
Immunoglobulin G / administration & dosage
-
Immunoglobulin G / adverse effects
-
Immunoglobulin G / therapeutic use
-
Immunoglobulins, Intravenous / administration & dosage
-
Immunoglobulins, Intravenous / adverse effects
-
Immunoglobulins, Intravenous / pharmacokinetics
-
Immunoglobulins, Intravenous / therapeutic use
-
Precision Medicine* / adverse effects
-
Precision Medicine* / methods
-
Treatment Outcome
Substances
-
Immunoglobulin G
-
Immunoglobulins, Intravenous